We found that higher levels of naïve B cells, plasma cells, naïve CD4 T cells, and activated mast cells were characteristic of TERTp-mutant glioma patients with high-risk scores in both TCGA cohorts, in association with a lower survival rate. The gene discussed is CD4; the disease is glioma.